非アルコール性脂肪性肝疾患(NAFLD)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 8
Therapeutics Development 9
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) – Overview 9
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) – Comparative Analysis 10
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics under Development by Companies 11
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics under Investigation by Universities/Institutes 13
Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Non Alcoholic Fatty Liver Disease (NAFLD) – Products under Development by Companies 17
Non Alcoholic Fatty Liver Disease (NAFLD) – Products under Investigation by Universities/Institutes 18
Non Alcoholic Fatty Liver Disease (NAFLD) – Companies Involved in Therapeutics Development 19
Conatus Pharmaceuticals Inc. 19
Daewoong Pharmaceutical Co., Ltd. 20
Galmed International Ltd. 21
Kyorin Pharmaceutical Co., Ltd. 22
Metabolic Solutions Development Company, LLC 23
Novartis AG 24
Phenex Pharmaceuticals AG 25
Raptor Pharmaceuticals Corp. 26
TCM Biotech International Corp 27
Tobira Therapeutics, Inc. 28
Verva Pharmaceuticals Limited 29
Zafgen Inc. 30
Non Alcoholic Fatty Liver Disease (NAFLD) – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 38
Drug Profiles 40
Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Aramchol – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
cenicriviroc – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
cysteamine DR – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DWP-10292 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
emricasan – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MAT-8800 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
MB-12066 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
methazolamide – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
MN-002 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MSDC-0602 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
oltipraz – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
pradigastat sodium – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Px-102 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Px-103 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Px-104 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Activate AMPK for Fatty Liver Disease – Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TCM-606F – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VVP-100-X – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ZGN-839 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Non Alcoholic Fatty Liver Disease (NAFLD) – Recent Pipeline Updates 66
Non Alcoholic Fatty Liver Disease (NAFLD) – Dormant Projects 80
Non Alcoholic Fatty Liver Disease (NAFLD) – Product Development Milestones 81
Featured News & Press Releases 81
Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 81
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 84
Disclaimer 84